Abstract:BACKGROUND: In a randomized trial, the early introduction of peanuts in infants at high risk for allergy was shown to prevent peanut allergy. In this follow-up study, we investigated whether the rate of peanut allergy remained low after 12 months of peanut avoidance among participants who had consumed peanuts during the primary trial (peanut-consumption group), as compared with those who had avoided peanuts (peanut-avoidance group).METHODS: At the end of the primary trial, we instructed all the participants to avoid peanuts for 12 months. The primary outcome was the percentage of participants with peanut allergy at the end of the 12-month period, when the participants were 72 months of age.RESULTS: We enrolled 556 of 628 eligible participants (88.5%) from the primary trial; 550 participants (98.9%) had complete primary-outcome data. The rate of adherence to avoidance in the follow-up study was high (90.4% in the peanut-avoidance group and 69.3% in the peanut-consumption group). Peanut allergy at 72 months was significantly more prevalent among participants in the peanut-avoidance group than among those in the peanut-consumption group (18.6% [52 of 280 participants] vs. 4.8% [13 of 270], P<0.001). Three new cases of allergy developed in each group, but after 12 months of avoidance there was no significant increase in the prevalence of allergy among participants in the consumption group (3.6% [10 of 274 participants] at 60 months and 4.8% [13 of 270] at 72 months, P=0.25). Fewer participants in the peanut-consumption group than in the peanut-avoidance group had high levels of Ara h2 (a component of peanut protein)-specific IgE and peanut-specific IgE; in addition, participants in the peanut-consumption group continued to have a higher level of peanut-specific IgG4 and a higher peanut-specific IgG4:IgE ratio.CONCLUSIONS: Among children at high risk for allergy in whom peanuts had been introduced in the first year of life and continued until 5 years of age, a 12-month period of peanut avoidance was not associated with an increase in the prevalence of peanut allergy. Longer-term effects are not known. (Funded by the National Institute of Allergy and Infectious Diseases and others; LEAP-On ClinicalTrials.gov number, NCT01366846.).

An Unintentional Randomized Trial of Early Environmental Exposure to Peanut: The Younger Siblings of LEAP Participants

Impact of peanut consumption in the LEAP Study: Feasibility, growth, and nutrition

Early Peanut Introduction in Primary Care: Evaluation of a Multicomponent Intervention

Early Introduction of Food Allergens and Risk of Developing Food Allergy

Risk subgroups and intervention effects among infants at high risk for peanut allergy: A model for clinical decision making

Effect of Avoidance on Peanut Allergy after Early Peanut Consumption

Optimising the management of peanut allergy by targeting immune plasticity

Consensus communication on early peanut introduction and the prevention of peanut allergy in high-risk infants

Peanut-specific IgG subclasses as biomarkers of peanut allergy in LEAP study participants

Early Peanut Immunotherapy in Children (EPIC) trial: protocol for a pragmatic randomised controlled trial of peanut oral immunotherapy in children under 5 years of age

Epitope-Specific IgE at 1 Year of Age Can Predict Peanut Allergy Status at 5 Years

Safety and adherence of early oral immunotherapy for peanut allergy in a primary care setting: a retrospective cross-sectional study

Design of the Intervention to Reduce Early Peanut Allergy in Children (iREACH): A practice‐based clinical trial

Do small effects matter more in vulnerable populations? an investigation using Environmental influences on Child Health Outcomes (ECHO) cohorts

The Risk Reduction of Accidental Exposure-Related Systemic Allergic Reactions Extrapolated Based on Food Challenge Data After 1 Year of Peanut Oral Immunotherapy

Peanut allergy in toddlers

Rates of New Peanut Allergy and Discontinuation Following Introduction in High-Risk Infants

Including young children in their food allergy care: A pilot study

Successful introduction of peanut in sensitized infants with reported reactions at home

Development of an innovative curriculum for paediatricians on peanut allergy prevention: How do we address current guidelines?

From Skin to Solution: Exploring Epicutaneous Immunotherapy for Peanut Allergy—A Systematic Review and Meta-Analysis